SecBot SecBot
SECBOTREPLAY Home › Report › IVVD

IVVD · Invivyd completed enrollment in the Phase 3 DECLARATION trial…

Invivyd · PRESS-RELEASE filed Jun 1, 2026 at 07:01 ET

At the news

BULLISHIMPACT 5/10

PRESS-RELEASE filed Jun 1, 2026 at 07:01 ET

Invivyd completed enrollment in the Phase 3 DECLARATION trial evaluating VYD2311 for prevention of symptomatic COVID-19. Top-line results are expected in late Q3 2026. The trial was upsized by ~500 subjects to enhance statistical power.

  • Enrollment completed in DECLARATION trial evaluating VYD2311 for COVID-19 prevention.
  • Trial is BLA-enabling, Phase 3, randomized, placebo-controlled with ~2,400 participants.
  • Sample size re-estimation added ~500 subjects to enhance statistical power.
  • Top-line results expected approximately late Q3 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access